{"id":15045,"date":"2012-06-30T00:04:00","date_gmt":"2012-06-29T22:04:00","guid":{"rendered":"http:\/\/www.fedaiisf.it\/quattro-farmaci-in-una-pillola-per-combattere-laids\/"},"modified":"2012-06-30T00:04:00","modified_gmt":"2012-06-29T22:04:00","slug":"quattro-farmaci-in-una-pillola-per-combattere-laids","status":"publish","type":"post","link":"https:\/\/www.fedaiisf.it\/en\/quattro-farmaci-in-una-pillola-per-combattere-laids\/","title":{"rendered":"Four drugs in one pill to fight AIDS"},"content":{"rendered":"

One new tablet combines four drugs,
making daily therapy easier for sufferers<\/strong><\/span><\/a><\/p>\n

 www.corriere.it \u2013 29 June 2012<\/span><\/p>\n

 <\/p>\n

 Aids, therapy with a "superpill" is possible<\/p>\n

<\/font><\/span><\/b><\/p>\n

A \u201csuper pill<\/em>\u201d able to replace four traditional anti-aids drugs<\/em>, combining them into a single solution. \u201cQuad<\/strong>\u201d, as it was called, has reached the conclusion of its third phase of experimentation<\/strong>and, the one that establishes its effectiveness and safety of assumption. The results of the study, coordinated by Dr. Edwin DeJesus have been published in the trade magazine The Lancet<\/em>.<\/font><\/p>\n

The research reveals the first positive results on the administration of <\/font>new<\/font><\/a> drug on patients at their first treatment for the treatment of<\/font>Hiv<\/font><\/a>. Already last May the Food and Drug Administration<\/strong> Americana, a lens responsible for giving the go-ahead for the marketing of medicines<\/strong>, he had expressed <\/font>opinion<\/font><\/a> favorable on the approval of the drug<\/strong>, awaiting the final decision next August, when it will decide whether to market the pill<\/strong> in question is possible.<\/font><\/p>\n

Quad is essentially based on four active ingredients: elvitegravir<\/em>, an integrase inhibitor (a key enzyme in the life cycle ofHiv<\/strong> which catalyzes its integration into the DNA<\/strong> of those who contract the virus, Editor's note), two anti-retrovirals such asemtricitabine<\/em> and the tenofovir disoproxil fumarate<\/em>, and the cobicistat,<\/em> potentiator capable of increasing the effectiveness of other drugs. A definitive approval of this drug would lead to a significant decrease in the discomfort of patients, now forced to take more drugs.<\/font><\/p>\n

Returning to the experimentation, during the first phase 700 North American volunteers were enrolled, divided into two specific groups. To those of the first<\/p>","protected":false},"excerpt":{"rendered":"

Una nuova compressa combina quattro farmaci, rendendo più facile la terapia giornaliera per i malati  www.corriere.it – 29 giugno 2012    Aids, terapia con una “superpillola” è possibile Una “superpillola” in grado di sostituire quattro farmaci anti-aids tradizionali, combinandoli in un’unica soluzione. “Quad”, così è stata chiamata, è arrivata alla conclusione della sua terza fase …<\/p>","protected":false},"author":1,"featured_media":9846,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[90],"tags":[],"class_list":["post-15045","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-fedaiisf-archivio-storico"],"amp_enabled":true,"_links":{"self":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts\/15045","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/comments?post=15045"}],"version-history":[{"count":0,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts\/15045\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/media\/9846"}],"wp:attachment":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/media?parent=15045"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/categories?post=15045"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/tags?post=15045"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}